Abstract: In the recent one year,much progress has been made on the clinical treatment of tuberculosis(TB)and many new drugs,regimens,therapies have already been tested and verified in clinical practice. In 2012,the most encouraging event was that Bedaquiline(TMC207)has been approved by USFDA to be used in multi-drug resistant TB treatment. Immunotherapy and therapeutic vaccines have also made some progress in clinical TB research. An international multi-center randomized,double-blinded,placebo-controlled study on heat inactivated Mycobacterium indicus pranii(M.w or MIP)plus glucocorticoids-contained chemotherapy to treat tuberculous exudative pericarditis is worthy of attention. This report presents the results of a randomized,double-blinded,placebo-controlled phase Ⅱb clinical trial by using the therapeutic vaccine V5 for hepatitis on the treatment of TB. For the respiratory endoscopic treatment,we mainly focused on assessing the value of the various methods in the treatment of tuberculosis,and systematically introduced the interventional treatment extracted from Guidelines for diagnosis and treatment of tracheal endobronchial TB(trail version).  The progress made by bone TB surgeon specially the new surgical treatment and application for spine TB has been added.  New approaches in the treatment of drug-resistant TB have been thoroughly researched. The treatment for Mtb/HIV co-infection has also made great progress,including 7 parts:prophylaxis for latent TB infection,treatment of TB,antiretroviral therapy,the interaction of anti-TB and antiretroviral drugs,the clinical efficacy,adverse events and immune reconstitution inflammatory syndrome.

Key words: Tuberculosis/therapy, Drug therapy, Immunotherapy, Surgical procedures, minimally invasive